Christopher Goetz to Follow-Up Studies
This is a "connection" page, showing publications Christopher Goetz has written about Follow-Up Studies.
Connection Strength
0.462
-
Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
Score: 0.101
-
Vibration therapy for Parkinson's disease: Charcot's studies revisited. J Parkinsons Dis. 2012; 2(1):23-7.
Score: 0.069
-
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
Score: 0.063
-
Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
Score: 0.055
-
The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
Score: 0.047
-
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
Score: 0.036
-
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338.
Score: 0.029
-
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50.
Score: 0.020
-
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
Score: 0.015
-
Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008 Nov 15; 23(15):2248-50.
Score: 0.014
-
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
Score: 0.013